Sari

Researchers are evaluating the effects of different doses of ticagrelor combined with aspirin in patients who have had a non-disabling non-cardioembolic ischemic stroke or a high-risk transient ischemic attack TIA. This study is a randomized, controlled, outcome assessor-blinded pilot trial involving 100 patients admitted to Bou-Ali Sina Hospital in Sari, Iran. The goal is to compare how well a lower dose of ticagrelor plus aspirin over six months works versus a higher dose plus aspirin for one month in preventing stroke recurrence within a year. Participants are divided into two groups. The intervention group receives aspirin 325 mg initially and ticagrelor 180 mg, followed by aspirin 80 mg daily and ticagrelor 90 mg twice daily for one month, then a reduced ticagrelor dose of 60 mg twice daily with aspirin 80 mg daily until six months. The control group receives aspirin 325 mg and ticagrelor 180 mg initially, then aspirin 80 mg daily and ticagrelor 90 mg twice daily for one month, followed by aspirin 80 mg daily alone until six months. After six months, both groups continue on aspirin alone. Participants will have follow-up visits at months 1, 3, 6, and 12 with a neurologist or neurology resident. Clinical data such as stroke severity scores and disability measures will be recorded. Researchers will monitor stroke recurrence confirmed by brain imaging as the primary outcome over 12 months, along with major bleeding events and cardiovascular events as secondary outcomes. Safety and efficacy will be closely tracked throughout the study period.

Warts caused by the human papillomavirus HPV are a common skin condition in children, affecting 10 to 20 percent of school-aged kids. These warts can cause physical discomfort and psychological stress, especially plantar warts that cause pain while walking. Current treatments are varied but often painful and may not be effective, with a high recurrence rate. This research aims to evaluate the combination of two topical treatments, 5-fluorouracil and calcipotriol, in children aged 4 to 18 with palmoplantar warts to understand their efficacy and safety. The study is a randomized, double-blind, placebo-controlled clinical trial comparing three treatments 5% fluorouracil cream plus 0.005% calcipotriol ointment, 5% fluorouracil cream plus placebo, and 0.005% calcipotriol ointment plus placebo. Each treatment is applied twice daily for 21 days to the affected palmoplantar areas. Placebo creams and ointments are designed to look and smell identical to the active treatments to maintain blinding. Participants will be monitored for treatment response by recording the number and size of warts at 2, 4, and 8 weeks after starting treatment. Adverse events will also be assessed at these time points. Photographs will be taken at baseline and during follow-up visits to document changes. This study is sponsored by Mazandaran University of Medical Sciences and will run from May 2025 to August 2026.